WO1999054314A1 - Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel - Google Patents
Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel Download PDFInfo
- Publication number
- WO1999054314A1 WO1999054314A1 PCT/EP1999/002496 EP9902496W WO9954314A1 WO 1999054314 A1 WO1999054314 A1 WO 1999054314A1 EP 9902496 W EP9902496 W EP 9902496W WO 9954314 A1 WO9954314 A1 WO 9954314A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- alkyl
- substituted
- hydrogen
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- the invention relates to new diphenyl-substituted 5-ring heterocycles, processes for their preparation and their use as medicaments.
- X is oxygen, sulfur or NR 6 ;
- R 1 is a Ci-CiQ-alkyl, C2-C-
- R ⁇ and R3 which may be the same or different are hydrogen, mercapto, -NR 6 R 7 , halogen, nitro, CF3, CN, -OR 8 , -C-C ⁇ o-alkyl, C2-C ⁇ o-alkenyl or C2-C ⁇ o- lkinyl,
- R 2 and R 3 Ce-Cio-aryl, aryl-Cj-Ce-alkyl, Cß-Ci Q-aryloxy;
- R4 and R5 which may be the same or different are hydrogen, mercapto, -NR 6 R 7 , halogen, nitro, CF 3 , CN, -OR 8 , C-
- R 4 and R 5 Cß-Cio-aryl, aryl-Ci-Ce-alkyl, Cß-Ci rj-aryloxy;
- R 6 is hydrogen, C3-C6-cycloalkyl, Ci-Cio-alkyl, C2-C-
- R6 Cö-C-jo-aryl, preferably phenyl, which may be replaced by halogen,
- R 7 is hydrogen, C3-C6-cycloalkyl, CjC-io-alkyl, C2-C ⁇ o-alkenyl or
- R 7 C ⁇ -C-io-aryl, preferably phenyl, which is optionally substituted by halogen,
- R ⁇ and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring, which may contain nitrogen, oxygen or sulfur as further heteroatoms, the heterocycle through a branched or unbranched alkyl group with 1 to 4 carbon atoms, through phenyl or may be substituted by benzyl;
- R 8 is hydrogen, C-
- Benzyl or phenyl radical which is optionally mono- or polysubstituted by OH, chlorine, bromine or OCH3, mean, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
- X is oxygen, sulfur or NR 6 ;
- R1 is a C - ⁇ - C alkyl radical, optionally one or more times
- R2 and R 3 which can be the same or different, are hydrogen, SH, -NR 6 R 7 ,
- R 2 and R 3 are phenyl, benzyl, phenyloxy
- R 4 and R5 which may be the same or different, are hydrogen, SH, -NR 6 R 7 ,
- R 4 and R 5 are phenyl, benzyl, phenyloxy
- R 6 is hydrogen, C3-C6-cycloalkyl, Ci-Cß-alkyl, C2-C6-alkenyl or
- R 6 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
- C ⁇ -C4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted; 4 R 7 hydrogen, C 3 -C6 cycloalkyl, Cj-C ⁇ -alkyl, C2-Ce-alkenyl or
- R 7 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
- -C-C-4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted;
- R6 and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain nitrogen or oxygen as further heteroatoms, where the heterocycle may be substituted by C 1 -C 4 -alkyl, phenyl or benzyl;
- R 8 is hydrogen, C - (- C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, a
- Benzyl or phenyl radical which is optionally substituted one or more times by OH, chlorine, bromine or OCH3, mean, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
- R1 a C ⁇
- -C-4-alkyl radical which is formed by -CONHSO 2 R 8 , -CONR 6 R 7 , -CH NOR 8 , -NR 6 R 7 , -NHCOR 8 , -NHCONR 6 R 7 , -NHCOOR 8 ,
- -OCONR 6 R 7 -S ⁇ 2NR 6 R 7 or is substituted by an N-oxide of the formula -NOR 6 R 7 ;
- 5 R 2 and R 3 which may be the same or different are hydrogen, -NR 6 R 7 , fluorine, chlorine, bromine, nitro, CF3, CN, -OR 8 , -C-C4-alkyl, phenyl, benzyl or phenyloxy;
- R 4 and R5 which can be the same or different are hydrogen, -NR 6 R 7 , fluorine, chlorine, bromine, nitro, CF3, CN, -OR 8 , C-
- R 8 is hydrogen, C3-C6-cycloalkyl or -CC-C4-alkyl, each of which can be substituted one or more times by hydroxyl, phenyl, benzyl or C-
- R6 phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
- C 1 -C 4 -alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted;
- R 7 is hydrogen, C 1 -C 8 -cycloalkyl or C 1 -C 4 -alkyi, each of which can be substituted one or more times by hydroxyl, phenyl, benzyl or C 1 -C 4 -alkoxy,
- R 7 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
- -C4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted; or
- R6 and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain nitrogen or oxygen as further heteroatoms, where the heterocycle can be substituted by C 1 -C 4 -alkyl, phenyl or benzyl;
- R 8 is hydrogen, C 1 -C 4 -alkyl, a benzyl or phenyl radical which is optionally substituted one or more times by OH, chlorine, bromine or OCH3, optionally in the form of their racemates, their enantiomers, in the form their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts. 6 According to the invention, preference is furthermore given to compounds of the general formula (I) in which
- Triazole, triazoline, triazoiidine, oxazole, oxazoline, oxadiazole but not 1, 2,4-oxadiazole, isoxazole or isoxazoline, each one or more times by Cj-C4-alkoxy, OH, O or C-
- -C4-alkyl can be substituted, wherein the Cj-C4-alkyl radical in turn can be substituted by fluorine, chlorine, bromine, OH or -NR 6 R 7 ;
- R 1 Ci -C4 alkyl which is substituted by -NR 6 R 7 or by an N-oxide of the formula - NOR 6 R 7 ;
- R 2 and R 3 which may be the same or different, are hydrogen, -NR 6 R 7 , fluorine,
- R 4 and R5 which may be the same or different are hydrogen, -NR 6 R 7 , fluorine,
- R6 is hydrogen or C 1 -C 4 -alkyl which is substituted one or more times by hydroxy
- Phenyl, benzyl or C 1 -C 4 alkoxy can be substituted
- R 7 is hydrogen or C-
- Phenyl, benzyl or C-i-C-t-alkoxy may be substituted, or
- R6 and R 7 together with the nitrogen atom form a saturated or unsaturated heterocycle selected from the group pyrrole, pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, the heterocycles mentioned being optionally by Methyl, ethyl, propyl or benzyl may be substituted; 7 R 8 is hydrogen, C 1 -C 4 -alkyl, benzyl or phenyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
- A is a radical selected from the group pyrrole, pyrazole, imidazole, imidazoline, imidazolidine, triazole, oxazole, oxazoiin, isoxazole, 1, 3,4-
- R 1 is C 1 -C 4 alkyl which is substituted by -NR 6 R 7 ;
- R 2 and R 3 are hydrogen
- R 4 and R 5 are hydrogen
- R6 is hydrogen, methyl, ethyl, propyl or butyl
- R 7 is hydrogen, methyl, ethyl, propyl or butyl; or
- R6 and R 7 together with the nitrogen atom form a saturated or unsaturated heterocycle selected from the group piperidine,
- Piperazine or morpholine optionally substituted by methyl, ethyl or
- Benzyl may be substituted, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts. 8 Of particular interest are compounds of the general formula (I) in which
- A is a radical selected from the group pyrrole, pyrazole, imidazole,
- R1 is an ethyl or propyl radical which is substituted by -NR 6 D R7
- R 2 and R 3 are hydrogen
- R 4 and R 5 are hydrogen
- R6 is hydrogen, methyl, ethyl, propyl or butyl
- R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
- R " ! Is an ethyl or propyl radical which is substituted by -NR 6 R 7 ;
- R 2 and R 3 are hydrogen
- R 4 and R 5 are hydrogen
- R 6 is hydrogen, methyl, ethyl, propyl or butyl
- R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, optionally in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
- R 1 is an ethyl or propyl radical which is substituted by -NR 6 R 7 ;
- R 2 and R 3 are hydrogen
- R 4 and R 5 are hydrogen
- R 6 is hydrogen, methyl, ethyl, propyl or butyl
- R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, optionally in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
- R 2 and R 3 are hydrogen
- R 4 and R 5 are hydrogen
- R 6 is methyl; 12 R 7 is methyl, optionally in the form of their racemates
- Enantiomers in the form of their diastereomers and their mixtures, if appropriate in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
- alkyl groups are branched and unbranched alkyl groups with ibis 10 carbon atoms, preferably 1-4 carbon atoms, for example: methyl, ethyl, n-propyl, iso- Propyl, butyl, iso-butyl, sec. Butyl, tert-butyl, pentyl, iso-pentyl, hexyl, heptyl and octyl.
- Me, Et, Bu or tBu are also used to denote the groups methyl, ethyl, butyl or tert-butyl.
- Alkenyl groups are branched and unbranched alkenyl groups with 2 to 10 carbon atoms, preferably 2 to 3 carbon atoms, provided that they have at least one double bond, for example also the alkyl groups mentioned above, provided that they have at least one double bond, such as for example vinyl (as long as no volatile enamines or enol ethers are formed), propenyl, iso-propenyl, butenyl, pentenyl, hexenyl.
- Alkynyl groups are alkynyl groups with 2 to 10 carbon atoms if they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl.
- Cycloalkyl radicals having 3 to 6 carbon atoms are, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which can also be substituted by branched or unbranched alkyl having 1 to 4 carbon atoms, hydroxy, and / or halogen or as previously defined.
- Halogen is generally referred to as fluorine, chlorine, bromine or iodine.
- aryl stands for an aromatic ring system with 6 to 10 carbon atoms which, unless otherwise described, can carry, for example, one or more of the substituents mentioned below: Ci-C ⁇ -alkyl, C-1-C5-alkyloxy, halogen, hydroxy, Mercapto, amino, alkylamino, dialkylamino, CF3, cyano, nitro, -CHO, -COOH, -COO-C-
- the preferred aryl radical is phenyl.
- N-linked cyclic radicals of the general formula NR ⁇ R 7 are: pyrrole, pyrroline, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, piperidine, piperazine, N-methylpiperazine, N-ethylpiperazine, N- (n-propyl ) -piperazine,
- the present invention describes compounds which surprisingly have a high affinity for the following receptor type: "Na + channel site 2" binding site. In addition, these compounds show antagonistic activity at the AMPA receptor. Based on these findings, the compounds according to the invention can be used in neurodegenerative diseases and brain ischemia of various origins.
- HCl gas is introduced into a solution of 100 g of benzonitrile and 60 ml of ethanol over a period of about 3 hours (weight gain: about 65 g).
- the mixture obtained is then left to stand at -25 ° C. for 6 days.
- aqueous phase is made alkaline with aqueous ammonia solution and twice with 17 dichloromethane extracted.
- the organic phase is dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (methanol). Yield: 500 mg (41%), light oil; Mp (fumarate): 184-186 ° C;
- a solution of 0.6 g of 1- (2-hydroxyphenyl) -5-methyl-3-phenyl-1, 2,4-triazole in 5 ml of 1,4-dioxane and a suspension of 0.27 are then slowly added g of potassium tert-butoxide in 5 ml of 1,4-dioxane.
- the mixture obtained in this way is stirred at about 100 ° C. for 3 hours.
- the solvent is then distilled off in vacuo, the remaining residue is taken up in ethyl acetate and the organic phase obtained in this way is extracted first with water and then with 2N HCl solution (aq.).
- the aqueous phases are made alkaline with aqueous ammonia solution and extracted with ethyl acetate.
- step b 3.4 g of the imidohydrazide prepared according to Example 5 (step b) are taken up with 12.1 g of triethyl orthoacetate in 50 ml of anhydrous ethanol and heated to reflux for 6 hours. After cooling to room temperature, the solvent is distilled off in vacuo and the remaining residue is taken up in diethyl ether. The organic phase thus obtained is washed three times with water, dried over MgSO 4 and the solvent is distilled off in vacuo. The remaining crude product is purified by chromatography on silica gel (toluene: ethyl acetate 80:20). Yield: 2 g (53%), slightly brownish oil;
- Example 8 4- (2-r2 (N, N-Dimethylamino) ethyl-phenyl) -2-phenyl-1,3-oxazole
- step (d) 4- (2-Hydroxyphenyl) -2-phenyl-1, 3-oxazole 0.7 g of 4- (2-benzyloxyphenyl) -2-phenyl-1, 3-oxazole according to step (d), 30 ml of tetrahydrofuran in In the presence of 0.1 g Pd / C catalyst hydrogenated at 20-60 ° C (5 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (dioxane: hexane 1: 5). Yield: 0.5 g (99%);
- step (a) 1 - (2-Benzyloxy-phenyl) -2-bromoethanone: 2.9 g of 2-benzyloxyacetophenone (Example 8, step (a)) are taken up in 50 ml of anhydrous chloroform and at about 2 ° C. with stirring slowly added a solution of 2.1 g bromine in 10 ml anhydrous chloroform. After complete conversion, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (toluene). Yield: 2.3 g (59%);
- step (c) 2.2 g of 4- (2-benzyloxyphenyl) -1-tert.butoxycarbonyl-2-phenyl-1, 3-imidazole according to step (c) are added in 35 ml of tetrahydrofuran in the presence of 0.2 g of Pd / C catalyst Room temperature hydrogenated (5 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (toluene). Yield: 0.75 g (43%);
- Example 12 5- ⁇ 2- [2 (N, N-Dimethylamino) ethnoxy-phenyl ⁇ -3-phenyl-1, 3,4-oxadiazol-2-one
- Example 3 in analogy to Example 12 (stage a).
- MeO a) 2- (2-methoxyphenyl) amino-1-phenyl-ethane-1-one A mixture of 10 g of 2-bromoacetophenone, 5.62 ml of 2-methoxyaniline and 5.85 g of Na2CÜ3 in ethanol is stirred for 18 hours . After dilution with water, the mixture is stirred for a further 30 minutes and the mixture is filtered. After washing the separated solid with water and hexane, 9.7 g of 2- (2-methoxyphenyl) amino-1-phenyl-ethan-1-one remain as a green-yellow solid. No further cleaning takes place.
- Example 18 4- (2- 2 (N.N-dimethylamino) ethvi1oxy-phenyl ⁇ -1-phenyl-pyrazole
- Example 17 in analogy to Example 12 (stage a). Mp: 205-208 ° C (diethyl ether);
- Example 20 1- ⁇ 2-f2 (N, N-Dimethylamino) ethyl-phenyl) -4-phenyl-1,3-dihydro-imidazol-2-one yy
- Example 22 4- ⁇ 2-r2 (N, N-Dimethylamino) ethyl1oxy-phenyl ⁇ -1-phenyl-1, 3-dihydro-imidazol-2-one
- step (c) 0.55 g 5- (2-benzyloxyphenyl) -2-phenyl-1, 3-oxazole according to step (c) are dissolved in 30 ml tetrahydrofuran in the presence of 0.1 g Pd / C catalyst (10%) at approx. Hydrogenated at 60 ° C (5.7 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (dioxane: hexane 3: 5). Yield: 0.38 g (95%);
- the compounds according to the invention show an affinity for or activity on different receptor types and have a neuroprotective effect.
- histamine and serotonin are of particular importance as neurotransmitters.
- concentrations of calcium and sodium ions in particular are changed.
- Brain lesions that can be induced with such substances are comparable to those associated with epilepsy and other neurodegenerative diseases - such as e.g. Huntington's disease and Alzheimer's disease - occur.
- Substances and ions that inhibit the activity of the glutamate receptors and the ion channel connected to this receptor - such as competitive and non-competitive antagonists of excitatory amino acids - protect brain cells from hypoxic or ischemic damage.
- the detection of the affinity for the "Na + Kanal site 2" binding site was carried out as described by GB Brown (J. Neurosci. 6 (1986) 2064). The testing was typically carried out at a test concentration of 10 ⁇ M.
- the compounds of the general formula (I) can be used for neurodegenerative diseases and brain ischemia of various origins. These include, for example: status epilepticus, hypoglycemia, hypoxia, anoxia, brain trauma, brain edema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotension, heart attack, intracranial pressure (increased intracranial pressure), ischemic and hemorrhagic strokes, global heart Polyneuropathy, tinitus, perinatal asphyxia, psychosis, schizophrenia, depression and Parkinson's disease.
- the compounds of the general formula (I) can be used alone or in combination with other active compounds according to the invention, optionally also in combination with other pharmacologically active compounds. Suitable forms of use are, for example, tablets, capsules, suppositories, solutions, in particular solutions for injection (SC, IV, IM) and infusion, juices, emulsions or dispersible powders.
- the proportion of the pharmaceutically active compound (s) should in each case be in the range from 0.1 to 90% by weight, preferably 0.5 to 50% by weight, of the total composition, i.e. in amounts sufficient to reach the dosage range given below.
- Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- auxiliaries for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- auxiliaries for example inert diluents
- coated tablets can be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
- the core can also consist of several layers in order to achieve a depot effect or to avoid incompatibilities.
- the coated tablet shell can also consist of several layers in order to achieve a depot effect, wherein the auxiliaries mentioned above for the tablets can be used.
- 45 juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar as well as a taste-improving agent, for example flavorings such as vanillin or orange extract. They can also contain suspending aids or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
- Injection and infusion solutions are used in the usual way, e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection bottles or ampoules or infusion bottles.
- isotonants e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvent
- the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by mixing the active ingredients with inert carriers, such as milk sugar or sorbitol, and encapsulating them in gelatin capsules.
- inert carriers such as milk sugar or sorbitol
- Suitable suppositories can be produced, for example, by mixing them with carrier agents, such as neutral fats or polyethylene glycol or its derivatives.
- carrier agents such as neutral fats or polyethylene glycol or its derivatives.
- auxiliary substances are water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils
- e.g. peanut or sesame oil monofunctional or polyfunctional alcohols (e.g. ethanol or glycerin), carriers such as e.g. natural rock flours (e.g. kaolins, clays, talc, chalk) synthetic rock flours (e.g. highly disperse silica and silicates), sugar (e.g. cane, milk and dextrose) emulsifiers (e.g. lignin, sufite liquor, methyl cellulose, starch and
- natural rock flours e.g. kaolins, clays, talc, chalk
- synthetic rock flours e.g. highly disperse silica and silicates
- sugar e.g. cane, milk and dextrose
- emulsifiers e.g. lignin, sufite liquor, methyl cellulose, starch and
- Polyvinylpyrrolidone and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate).
- lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
- the application is carried out in the usual way, preferably parenterally - in particular by infusion - intravenously.
- the tablets can of course also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate, in addition to the carrier substances mentioned Contain 46 different additives, such as starch, preferably potato starch, gelatin and the like.
- Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
- the active ingredients can be mixed with various flavor enhancers or colorants.
- solutions of the active ingredients can be used using suitable liquid carrier materials.
- the dosage for intravenous use is 1 - 1000 mg per hour, preferably between 5 - 500 mg per hour.
- the finely ground active ingredient, milk sugar and part of the corn starch are mixed together.
- the mixture is sieved, whereupon it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
- the granules, the rest of the corn starch and the magnesium stearate are sieved and mixed together.
- the mixture is compressed into tablets of a suitable shape and size.
- the finely ground active ingredient, part of the corn starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the rest of the corn starch and water to form a granulate which is dried and sieved.
- the sodium carboxymethyl starch and the magnesium stearate are added, and the mixture is mixed and pressed into tablets of a suitable size.
- the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, sodium chloride is added as the isotonic agent, the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed .
- the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT99920661T ATE270665T1 (de) | 1998-04-17 | 1999-04-14 | Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| MXPA00009474A MXPA00009474A (es) | 1998-04-17 | 1999-04-14 | Nuevos heterociclos de 5 anillos sustituidos con difenilo, procedimientos para su preparacion, asi como su empleo como medicamentos. |
| EP99920661A EP1071670B1 (de) | 1998-04-17 | 1999-04-14 | Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| DE59909917T DE59909917D1 (de) | 1998-04-17 | 1999-04-14 | Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| CA002322195A CA2322195C (en) | 1998-04-17 | 1999-04-14 | Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| JP2000544653A JP4589531B2 (ja) | 1998-04-17 | 1999-04-14 | 新規ジフェニル置換5員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19816880A DE19816880A1 (de) | 1998-04-17 | 1998-04-17 | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| IT98MI000818A IT1300055B1 (it) | 1998-04-17 | 1998-04-17 | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| DE19816880.2 | 1998-04-17 | ||
| ITMI98A000818 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999054314A1 true WO1999054314A1 (de) | 1999-10-28 |
Family
ID=26045525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1999/002496 Ceased WO1999054314A1 (de) | 1998-04-17 | 1999-04-14 | Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6255327B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1071670B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4589531B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE270665T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2322195C (cg-RX-API-DMAC7.html) |
| DE (2) | DE19816880A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2224652T3 (cg-RX-API-DMAC7.html) |
| IT (1) | IT1300055B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA00009474A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999054314A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1070708A1 (en) * | 1999-07-21 | 2001-01-24 | F. Hoffmann-La Roche Ag | Triazole and imidazole derivatives |
| WO2002060877A1 (en) * | 2001-01-29 | 2002-08-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives |
| US9051342B2 (en) | 2004-10-13 | 2015-06-09 | Ptc Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases |
| CN106573894A (zh) * | 2014-08-13 | 2017-04-19 | 日本曹达株式会社 | 二芳基咪唑化合物和有害生物防除剂 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579880B2 (en) * | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
| US8829198B2 (en) | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| AU2004289694B2 (en) * | 2003-11-10 | 2010-05-13 | Merck Sharp & Dohme Corp. | Substituted triazoles as sodium channel blockers |
| JP2007527917A (ja) * | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| WO2008131148A1 (en) * | 2007-04-19 | 2008-10-30 | The Trustees Of The University Of Pennsylvania | Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques |
| WO2009111611A2 (en) | 2008-03-05 | 2009-09-11 | Proteotech Inc. | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
| CN102060798A (zh) * | 2011-01-04 | 2011-05-18 | 复旦大学 | 2-(1-氢-4-四唑)-4′- 甲基联苯及其衍生物的合成方法 |
| WO2012118935A1 (en) | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2152345A1 (en) * | 1971-09-06 | 1973-04-27 | Roussel Uclaf | Alpha-(2-thiazolyl)oxyalkanoic acids and derivatives - - with analgesic,antiinflammatory and antipyretic activity |
| EP0248594A2 (en) * | 1986-05-29 | 1987-12-09 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same |
| EP0513387A1 (en) * | 1990-11-30 | 1992-11-19 | Otsuka Pharmaceutical Co., Ltd. | Active oxygen inhibitor |
| DE19528189A1 (de) * | 1995-08-01 | 1997-02-06 | Basf Ag | Benzolderivate mit einem heterocyclischen Rest |
| WO1998015274A1 (en) * | 1996-10-07 | 1998-04-16 | Eli Lilly And Company | Novel compounds useful as neuro-protective agents |
| WO1998017652A1 (de) * | 1996-10-18 | 1998-04-30 | Boehringer Ingelheim Pharma Kg | Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| WO1998027108A2 (en) * | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5305E (fr) * | 1905-06-17 | 1906-02-22 | Edouard Pellorce | Appareil électrique pour l'allumage des moteurs à explosion |
| DE1545806A1 (de) * | 1951-01-28 | 1969-11-27 | Hoechst Ag | Verfahren zur Herstellung von heterocyclischen Verbindungen |
| FR1356901A (fr) * | 1958-03-13 | 1964-04-03 | Nouveaux aminoétheroxydes, aminothioéthers et aminoesters dérivés du pyrrole, etleur procédé de préparation | |
| FR2244462A1 (en) * | 1973-09-25 | 1975-04-18 | Delalande Sa | Antihypertensive, 5-hydroxy methyl 1,2,4-triazoles - prepd. from aniline and a hydroxy methyl 1,3,4-oxadiazole |
| SU753084A1 (ru) * | 1979-03-23 | 1983-01-23 | Ростовский Ордена Трудового Красного Знамени Государственный Университет | Способ получени 1-[2-алкил(аралкил)аминоарил -4-арилимидазолов общей формулы |
| US4370336A (en) * | 1979-06-11 | 1983-01-25 | Gruppo Lepetit S.P.A. | 3,5-Disubstituted-1H-1,2,4-triazole derivatives as antifertility agents |
| US4379155A (en) * | 1979-06-11 | 1983-04-05 | Gruppo Lepetit S.P.A. | 3,5-Disubstituted-1H-1,2,4-triazole derivatives |
| JP2928307B2 (ja) * | 1989-02-03 | 1999-08-03 | エーザイ株式会社 | ピロリジン誘導体 |
| FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US5411977A (en) * | 1993-03-31 | 1995-05-02 | The Dupont Merck Pharmaceutical Company | Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and antithrombotic agents |
-
1998
- 1998-04-17 IT IT98MI000818A patent/IT1300055B1/it active IP Right Grant
- 1998-04-17 DE DE19816880A patent/DE19816880A1/de not_active Withdrawn
-
1999
- 1999-04-13 US US09/290,931 patent/US6255327B1/en not_active Expired - Lifetime
- 1999-04-14 AT AT99920661T patent/ATE270665T1/de active
- 1999-04-14 CA CA002322195A patent/CA2322195C/en not_active Expired - Fee Related
- 1999-04-14 EP EP99920661A patent/EP1071670B1/de not_active Expired - Lifetime
- 1999-04-14 DE DE59909917T patent/DE59909917D1/de not_active Expired - Lifetime
- 1999-04-14 JP JP2000544653A patent/JP4589531B2/ja not_active Expired - Fee Related
- 1999-04-14 WO PCT/EP1999/002496 patent/WO1999054314A1/de not_active Ceased
- 1999-04-14 ES ES99920661T patent/ES2224652T3/es not_active Expired - Lifetime
- 1999-04-14 MX MXPA00009474A patent/MXPA00009474A/es active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2152345A1 (en) * | 1971-09-06 | 1973-04-27 | Roussel Uclaf | Alpha-(2-thiazolyl)oxyalkanoic acids and derivatives - - with analgesic,antiinflammatory and antipyretic activity |
| EP0248594A2 (en) * | 1986-05-29 | 1987-12-09 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same |
| EP0513387A1 (en) * | 1990-11-30 | 1992-11-19 | Otsuka Pharmaceutical Co., Ltd. | Active oxygen inhibitor |
| DE19528189A1 (de) * | 1995-08-01 | 1997-02-06 | Basf Ag | Benzolderivate mit einem heterocyclischen Rest |
| WO1998015274A1 (en) * | 1996-10-07 | 1998-04-16 | Eli Lilly And Company | Novel compounds useful as neuro-protective agents |
| WO1998017652A1 (de) * | 1996-10-18 | 1998-04-30 | Boehringer Ingelheim Pharma Kg | Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| WO1998027108A2 (en) * | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| C P TAYLOR ET AL: "TRENDS IN PHARMACOLOGICAL SCIENCES", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 16, 1 September 1995 (1995-09-01), pages 309 - 316, XP002090490, ISSN: 0165-6147 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1070708A1 (en) * | 1999-07-21 | 2001-01-24 | F. Hoffmann-La Roche Ag | Triazole and imidazole derivatives |
| US6265426B1 (en) | 1999-07-21 | 2001-07-24 | Hoffmann-La Roche Inc. | Triazole derivatives |
| WO2002060877A1 (en) * | 2001-01-29 | 2002-08-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US6667335B2 (en) | 2001-01-29 | 2003-12-23 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US6683097B2 (en) | 2001-01-29 | 2004-01-27 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US9051342B2 (en) | 2004-10-13 | 2015-06-09 | Ptc Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases |
| CN106573894A (zh) * | 2014-08-13 | 2017-04-19 | 日本曹达株式会社 | 二芳基咪唑化合物和有害生物防除剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2224652T3 (es) | 2005-03-01 |
| JP2002512235A (ja) | 2002-04-23 |
| US6255327B1 (en) | 2001-07-03 |
| DE19816880A1 (de) | 1999-10-21 |
| EP1071670B1 (de) | 2004-07-07 |
| IT1300055B1 (it) | 2000-04-05 |
| CA2322195C (en) | 2008-02-26 |
| ITMI980818A1 (it) | 1999-10-17 |
| CA2322195A1 (en) | 1999-10-28 |
| DE59909917D1 (de) | 2004-08-12 |
| EP1071670A1 (de) | 2001-01-31 |
| MXPA00009474A (es) | 2002-08-12 |
| JP4589531B2 (ja) | 2010-12-01 |
| ATE270665T1 (de) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0934288B1 (de) | Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| DE3788385T2 (de) | Pyrimidin-Derivate. | |
| EP0136658B1 (de) | 1-Benzyl-aminoalkyl-pyrrolidinone und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DD237510A5 (de) | Verfahren zur herstellung von substituierten imidazo-(1,5-a)pyridin-derivaten | |
| EP1071670B1 (de) | Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel | |
| DE2235544A1 (de) | 1-alkyl-3,5-disubstituierte 1,2,4triazolderivate und verfahren zu deren herstellung | |
| EP1071671B1 (de) | Triazolone mit neuroprotektiver wirkung | |
| DE1958201A1 (de) | Neue substituierte N-Allyl-2-arylamino-imidazoline-(2) und Verfahren zu deren Herstellung | |
| DE3435745A1 (de) | 2-(3-(4-(3-phenyl)-1-piperazinyl)propyl)-2,4-dihydro-3h-1,2,4-triazol-3-on verbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel | |
| EP1611107A1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen | |
| DE60010126T2 (de) | Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| DE2633679A1 (de) | 4,5-dihydro-2-niederalkoxycarbonylamino-4-phenylimidazole und derivate davon mit substituierter phenylgruppe | |
| DD156808A5 (de) | Verfahren zur herstellung von 1,1-diphenyl 1-2-(1.2.4.-ariazol-1-yl)-aethan-1-oben | |
| EP0200947B1 (de) | 1,3-Disubstituierte Imidazoliumsalze | |
| CH618438A5 (cg-RX-API-DMAC7.html) | ||
| EP0298921B1 (de) | 1,2-Benzisoxazole und 1,2-Benzisothiazole | |
| DD282457A5 (de) | Verfahren zur herstellung neuer heterocyclischer derivate | |
| EP1077950B1 (de) | Neue diphenyl-substituierte 6-ring heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel | |
| DE68913167T2 (de) | Indol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. | |
| DE69707080T2 (de) | Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel | |
| EP0037471B1 (de) | 1-Aroyl-2-phenylamino-2-imidazoline, ihre Herstellung und diese enthaltende Arzneimittel | |
| DE2709842A1 (de) | Benzodiazepine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| EP0129509B1 (de) | Triazol(2,3-c)(1,3)benzodiazepine, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung | |
| EP0478941B1 (de) | Arzneimittel welche substituierte 2-Cyclohexen-1yl-amin-Derivate enthalten und ihre Verwendung zur Bekämpfung von Krankheiten | |
| AT362358B (de) | Verfahren zur herstellung von neuen 6-aryl-2,3, 6,7-tetrahydro-5h-pyrrolo (1,2-a)imidazolen und von deren saeureadditionssalzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999920661 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2322195 Country of ref document: CA Ref country code: CA Ref document number: 2322195 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/009474 Country of ref document: MX |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999920661 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1999920661 Country of ref document: EP |